SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) today announced that it has now received more than 75 orders for the Genome Analyzer, the Company’s DNA sequencing, gene expression profiling, and micro-RNA analysis platform. In addition to the Broad Institute, which has already installed 16 Genome Analyzers out of a near term goal of 20, demand for the sequencing system has increased significantly among genome centers, core laboratories, industrial laboratories, and individual academic centers worldwide.
